https://www.live-feeds.com/feed/fda-advisory-panel-endorses-grail-blood-test-for-cancer-saying-benefits-outweigh-risksContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/fda-advisory-panel-endorses-grail-blood-test-for-cancer-saying-benefits-outweigh-riskshttps://www.live-feeds.com/feed/fda-advisory-panel-endorses-grail-blood-test-for-cancer-saying-benefits-outweigh-risks#u85481Sat, 26 Sep 2026 20:30:21 +0000An FDA advisory panel voted that the benefits of Grail's multi-cancer early detection blood test outweigh its risks. The test screens for 50 different types of cancer. While the panel provides a positive recommendation, the test still requires formal FDA approval before it can be widely adopted. This approval is the primary factor determining if Medicare and other private health insurers will cover the cost of the screening for patients.Why it mattersEarly detection of cancer typically improves survival rates but often requires invasive procedures. A single blood test for 50 cancers would